← Back to Search

Radiopharmaceutical

Radioembolization with Yttrium-90 for Liver Cancer

N/A
Recruiting
Led By Shamar J Young, Young
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Lesion >2.0 cm which is amenable to percutaneously biopsied
ECOG status ≤ 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 4, 12 weeks
Awards & highlights

Study Summary

This trial will study the effects of a cancer treatment, radioembolization, on the immune system.

Who is the study for?
This trial is for adults over 22 with liver cancer diagnosed by biopsy or imaging, who have a life expectancy of more than 3 months and can perform daily activities with some limitations. They must have a tumor larger than 2 cm that can be biopsied, normal bilirubin levels, and acceptable blood clotting functions.Check my eligibility
What is being tested?
The study tests the effects of Yttrium-90 radioembolization on the immune system in liver cancer patients. It involves monitoring changes in immune cells from blood samples and tissue biopsies before and after treatment to understand how this therapy influences immunity.See study design
What are the potential side effects?
While specific side effects are not listed here, radioembolization procedures like those involving Yttrium-90 typically carry risks such as fatigue, abdominal pain, nausea, potential liver damage, feverish symptoms known as post-embolization syndrome.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a tumor larger than 2 cm that can be biopsied with a needle.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Select...
My liver cancer was confirmed by a biopsy or imaging.
Select...
I am older than 22 years.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 4, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 4, 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Change in concentrations of PBMC
Change in concentrations of cytokines
Change in concentrations of immune cell infiltration into the tumor

Trial Design

1Treatment groups
Experimental Treatment
Group I: Yttrium-90Experimental Treatment1 Intervention
This single arm study is to evaluate immunologic changes following the treatment of primary or secondary malignancies of the liver utilizing beta-emitting, Yttrium-90.

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,371 Previous Clinical Trials
1,588,051 Total Patients Enrolled
Shamar J Young, YoungPrincipal InvestigatorUniversity of Minnesota

Media Library

Yttrium-90 (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT03889093 — N/A
Liver Cancer Research Study Groups: Yttrium-90
Liver Cancer Clinical Trial 2023: Yttrium-90 Highlights & Side Effects. Trial Name: NCT03889093 — N/A
Yttrium-90 (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03889093 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enlistment open for this research endeavor?

"Confirmed. According to clinicaltrials.gov, this research study is presently enrolling participants. This project was opened on August 9th 2018 and last revised on October 28th 2022. In total, the trial seeks 30 individuals from a single medical centre."

Answered by AI

How many individuals are being monitored in this research project?

"Affirmative. As evidenced on clinicaltrials.gov, this medical study is currently searching for participants after being published in August of 2018 and edited lastly at the end of October 2022. The trial requires 30 people from 1 centre to participate."

Answered by AI
~5 spots leftby Mar 2025